Imagine you have used a generative artificial intelligence (AI) tool such as ChatGPT to tidy up notes you took while in a meeting. Your colleague comments on how clear they are. You don’t disclose it ...

Replimune Group, Inc.'s RP1 has failed at the FDA twice, but Makary's resignation keeps a resubmission possible. REPL's cash runway stands at under a year; workforce cuts and RP1 discontinuation are ...

OpenEvidence, an AI-powered medical search tool, has become a fast friend to America’s doctors and is now used by nearly two-thirds of physicians. Your doctor is probably using AI, even if they ...

The company said that it had identified, for the first time, hackers using artificial intelligence to discover an unknown bug. The attempted attack represents “a taste of what’s to come,” one expert ...

The website for the popular JDownloader download manager was compromised earlier this week to distribute malicious Windows and Linux installers, with the Windows payload found deploying a Python-based ...

Jason Chun is a CNET writer covering a range of topics in tech, home, wellness, finance and streaming services. He is passionate about language and technology, and has been an avid writer/reader of ...

Google is rebranding Circle to Search’s full-screen feature to “Ask about screen,” allowing it to process URLs and PDF data instead of just visible screen content. This update, currently in beta ...

If Python developers have one consistent gripe about their beloved language, it tends to be this: Why is it so hard to take a Python program and deploy it as a standalone artifact, the way C, C++, ...

Use left and right arrow keys to seek audio. Does your Windows PC feel slow, freeze during simple tasks, and show RAM usage spiking close to 100% in Task Manager? While heavy RAM usage by processes ...

News is breaking today that Replimune Group, Inc.'s (REPL) Biologics License Application ("BLA") requesting approval for its drug candidate RP1 (vusolimogene oderparepvec) in the indication of anti-PD ...

FDA has now rejected Replimune’s melanoma immunotherapy RP1 on two separate occasions The drug was under consideration for use with Bristol Myers Squibb’s (BMY) Opdivo therapy Regulators maintained ...

This content can't be displayed right now. To view this embed, please accept targeting cookies. It's loaded from a third party and requires that permission to appear. Manage cookie preferences When ...